Last Updated: 2026

Stoke Therapeutics

Rank#4923

Market Cap1.87B

CountryUnited States

Summary

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

History

Stoke was founded in 2017 by a team of leading scientists and clinicians to develop potential treatments for severe genetic diseases. The company leverages a piece of groundbreaking gene-silencing technology called Amplifying Ribonucleic Acid (ARNA) to develop new therapies for diseases without established solutions.

Mission

Stoke Therapeutics is committed to bringing new and innovative treatments to people with severe genetic diseases by unlocking the body’s natural process to control gene expression.

Vision

At Stoke Therapeutics, we envision a world in which every person with a severe genetic disease can expect a potential solution from a reliable source.

References

https://in.investing.com/equities/stoke-therapeutics-inc

https://finance.yahoo.com/quote/STOK/profile?p=STOK

https://www.crunchbase.com/organization/stoke-therapeutics

https://companiesmarketcap.com/

https://www.stoketherapeutics.com

Leadership team

Dr. Edward M. Kaye M.D., Ph.D. (CEO & Director)

Dr. Adrian R. Krainer Ph.D. (Co-Founder, Independent Director & Member of Scientific Advisory Board)

Mr. Stephen J. Tulipano CPA, CPA, MBA (Chief Financial Officer)

Products / Services

Biotechnology, Health Care, Pharmaceutical, Therapeutics

Number of Employees

100 - 500

Address

Bedford, Massachusetts, United States

Established

2014-01-01

Company Registration

SEC CIK number: 0001623526

Revenue

5M - 20M

Traded as

STOK

Website

https://www.stoketherapeutics.com

Social Media

Last Updated: 2026

Stoke Therapeutics

Rank#4923

Market Cap1.87B

CountryUnited States

Summary

History

Mission

Stoke Therapeutics is committed to bringing new and innovative treatments to people with severe genetic diseases by unlocking the body’s natural process to control gene expression.

Vision

At Stoke Therapeutics, we envision a world in which every person with a severe genetic disease can expect a potential solution from a reliable source.

References

https://in.investing.com/equities/stoke-therapeutics-inc

https://finance.yahoo.com/quote/STOK/profile?p=STOK

https://www.crunchbase.com/organization/stoke-therapeutics

https://companiesmarketcap.com/

https://www.stoketherapeutics.com

Leadership team

Dr. Edward M. Kaye M.D., Ph.D. (CEO & Director)

Dr. Adrian R. Krainer Ph.D. (Co-Founder, Independent Director & Member of Scientific Advisory Board)

Mr. Stephen J. Tulipano CPA, CPA, MBA (Chief Financial Officer)

Products / Services

Biotechnology, Health Care, Pharmaceutical, Therapeutics